Celgene International Sárl To Present Long-Term Efficacy And Safety Data On Oral OTEZLA® (Apremilast) In Plaque Psoriasis And Psoriatic Arthritis At European Academy Of Dermatology And Venereology Congress

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that the latest research findings on OTEZLA® (apremilast), the Company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4), in plaque psoriasis and psoriatic arthritis will be presented at the 23rd European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, October 8 – 12, 2014. In total, 11 abstracts (two oral presentations and nine e-Posters) will be presented at the meeting.

OTEZLA data to be presented include long-term (52-week) results from Celgene’s pivotal trial, ESTEEM 2 and pooled analyses of safety and tolerability results from the ESTEEM 1 and 2 studies in patients with moderate to severe plaque psoriasis. Additional analyses will evaluate the effect of OTEZLA on pruritus (itching), difficult-to-treat areas such as nail and scalp, and palmoplantar (hand and feet) psoriasis, work productivity and improvements in health-related quality of life.

Help employers find you! Check out all the jobs and post your resume.

Back to news